EmergingLongevityMetabolic

SLU-PP-332

Exercise Mimetic

Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator

Half-life

Under investigation (no human PK data)

Chain length

Not applicable

Reference frequency

Research only - not approved for human use

Research overview

DoseGear research brief

Groundbreaking synthetic compound from Saint Louis University functioning as pan-estrogen-related receptor agonist with preferential ERRα activity. Activates metabolic pathways engaged during physical exercise without physical activity requirement.

Mechanism of action

Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1. 8-fold, enhances oxidative phosphorylation and ATP production.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Synthetic small molecule associated with Saint Louis University research.

What it is researched for

Preclinical exercise-pathway and metabolic-disease research through estrogen-related-receptor agonism, especially ERRα.

Research observation window

A cited intraperitoneal obese-mouse study used 28 days; a human response window is not reported.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
Standard Metabolic Protocol	50 mg/kg (animal dosing)	Twice daily	Intraperitoneal injection (IP)
Acute Exercise Enhancement	50 mg/kg (animal dosing)	Single dose 1 hour pre-exercise	Intraperitoneal injection (IP)
Extended Treatment	50 mg/kg (animal dosing)	Twice daily for 4-8 weeks	Intraperitoneal injection (IP)

Reference cycle

No human protocols established

Reference storage

2-8°C refrigerated for research use

Safety context

Reported side effects

Animal studies show favorable safety with no severe effects at therapeutic doses
Well-tolerated in rodents and canines
No liver, kidney, or cardiac toxicity documented
No lean mass loss
Does not suppress hormones or act as stimulant
Minor plasma cholesterol and liver enzyme changes in some studies

Contraindications & cautions

NOT FOR HUMAN USE - no approved human dose
No human clinical trials conducted
Potential interaction with diabetes medications

Scientific references

01
A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Scientific citationA Synthetic ERR Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics (2024).
02
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
Scientific citationSynthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology (2023).
03
Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney
Scientific citationEstrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. American Journal of Pathology (2023).
04
Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
Scientific citationNovel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation (2024).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity